Asthma: Explore key pipeline products.
By Jacoba Procter, Content Manager
22 October 2014
I joined Datamonitor Healthcare as an analyst at the end of 2009 and I worked for a number of years covering immunology ...
Read full bio
BRAND NEW: Our pipeline report now contains an interactive early-phase forecast model and a chapter on early-phase opportunities within asthma – exclusive content you’ll only find at Datamonitor Healthcare.
Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated. Biologics in the pipeline for asthma aiming to treat this patient population. Datamonitor Healthcare has provided an in-depth analysis of pipeline products in the US, Japan and five major EU markets, including new clinical data and an evaluation of clinical and commercial drug attributes.
How will our asthma pipeline report benefit you?
- Target unmet needs
Understand which populations in asthma are inadequately treated and how late-stage therapies will target these patient groups, enabling you to identify where there is still room for opportunities and what needs are currently being overlooked.
- Identify investment opportunities
Explore the future developments in the treatment of asthma, understanding how once-daily fixed-dose inhalers such as Breo will change therapy and how asthma therapy will progress, allowing you to identify what therapies you should be investing in to gain potential commercial success within the market.
- Gain competitive overview
Understand how biologics will position themselves within the market and compete against each other by comparing their clinical and commercial attributes, allowing you to benchmark your product against that with the most potential for success.
- Identify early-phase opportunities
Access our exclusive interactive 20-year early-phase forecast model with clearly identified opportunities to assist in your decision-making.
Key questions answered:
- What pipeline therapies are set to compete successfully in the asthma market?
- How successful has clinical development program been for biologics so far?
- How will targeted therapies fit into the future of treatment within the market?
|Drug List:||Companies Mentioned:|
Posted in Respiratory.